Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Ming Han, Alli Murugesan, Nizar J. Bahlis, Kevin Song, Darrell White, Christine Chen, Matthew D. Seftel, Kang Howsen-Jan, Donna Reece, Keith Stewart, Yagang Xie, Annette E. Hay, Lois Shepherd, Marina Djurfeldt, Liting Zhu, Ralph M. Meyer, Bingshu E. Chen, Tony Reiman

Blood (2016) 128 (5): 732–735.

https://doi.org/10.1182/blood-2016-06-716902

Published: 2016

Includes: Supplemental data

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Blood (2013) 121 (9): 1517–1523.

https://doi.org/10.1182/blood-2012-09-451872

Published: 2013

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

Blood (2010) 116 (25): 5650–5659.

https://doi.org/10.1182/blood-2010-06-288613

Published: 2010

Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Blood (2010) 116 (21): 111.

https://doi.org/10.1182/blood.V116.21.111.111

Published: 2010

Journal Articles

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A. Keith Stewart, Suzanne Trudel, MD, MSC, FRCPC, Nizar J Bahlis, MD, Darrell J White, MD, Waleed Sabry, MSc, MD, Andrew Belch, MD, Tony Reiman, MD, Jean Roy, MD, FRCPC, Chaim Shustik, MD, Michael J. Kovacs, MD, FRCPC, Jonathan Sussman, Ralph M. Meyer, MD, Erica L Harnett, M.Sc., Danila Oana, Judy A Chapman, Lois Shepherd, MD

Blood (2010) 116 (21): 39.

https://doi.org/10.1182/blood.V116.21.39.39

Published: 2010

Journal Articles

Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.

Chaim Shustik, MD, Stephen Harding, PhD, Keyue Ding, Liting Zhu, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD, PhD, Lois Shepherd, MD, Melanie Robson

Blood (2009) 114 (22): 2631.

https://doi.org/10.1182/blood.V114.22.2631.2631

Published: 2009

Journal Articles

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Laurie H. Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Guy Cantin, MD, Morel Rubinger, MD, Bernard Lemieux, MD, Sanraj Basi, MD, Kevin R Imrie, MD, Randy D. Gascoyne, Bingshu Chen, PhD, Marina Djurfeldt, MSc, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2009) 114 (22): 407.

https://doi.org/10.1182/blood.V114.22.407.407

Published: 2009

Journal Articles

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Laurie H Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Morel Rubinger, MD, FRCPC, Kevin R Imrie, MD, Judy-Anne W Chapman, PhD, Marina Djurfeldt, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2008) 112 (11): 1576.

https://doi.org/10.1182/blood.V112.11.1576.1576

Published: 2008

Journal Articles

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Jacob M. Rowe, MD, Xiaochun Li, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Charles A. Schiffer, MD, Peter H. Wiernik, MD, Mark R. Litzow, MD, Larry D. Cripe, MD, Hillard M. Lazarus, MD, Elisabeth Paietta, Ph.D, Gordon W. Dewald, MD, Howard J. Weinstein, MD, Angela K. Ogden, MD, William G. Woods, MD, Lois Shepherd, MD, James H. Feusner, MD, Clara D. Bloomfield, MD, Martin S. Tallman, MD

Blood (2005) 106 (11): 546.

https://doi.org/10.1182/blood.V106.11.546.546

Published: 2005

Journal Articles

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

John Gregory, MD, Haesook Kim, PhD, Todd Alonzo, MD, Rob Gerbing, PhD, Angela Ogden, MD, William Woods, MD, Howard Weinstein, MD, Lois Shepherd, MD, Charles Schiffer, MD, Frederick Appelbaum, MD, Cheryl Willman, MD, Peter Wiernik, MD, Jacob Rowe, MD, Martin Tallman, MD, James Feusner, MD

Blood (2005) 106 (11): 894.

https://doi.org/10.1182/blood.V106.11.894.894

Published: 2005

Journal Articles

Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.

Michael J. Kovacs, MD, FRCPC, Judy-Anne W. Chapman, PhD, Lois Shepherd, MD, FRCPC, Ralph Meyer, MD, FRCPC, Michael Keeney, ART, FIMLS, Karen MacKinnon, MLT, Keith Stewart, MD, FRCPC, Nancy Paul, PhD, The NCIC CTG Investigators on MY.10.

Blood (2005) 106 (11): 2561.

https://doi.org/10.1182/blood.V106.11.2561.2561

Published: 2005

Journal Articles

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

John C. Byrd, Kanti Rai, Bercedis L. Peterson, Frederick R. Appelbaum, Vicki A. Morrison, Jonathan E. Kolitz, Lois Shepherd, John D. Hines, Charles A. Schiffer, Richard A. Larson

Blood (2005) 105 (1): 49–53.

https://doi.org/10.1182/blood-2004-03-0796

Published: 2005

Journal Articles

Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.

Martin S. Tallman, MD, Haesook T. Kim, PhD, Charles A. Schiffer, MD, Frederick R. Appelbaum, MD, James H. Feusner, MD, Angela K. Ogden, MD, Lois Shepherd, MD, Cheryl L. Willman, MD, Clara D. Bloomfield, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Peter H. Wiernik, MD, Guillermo Martin, MD, Chelo Rayon, MD, Javier de la Serna, MD, Concha Rivas, MD, Jose D. Gonzalez-San Miguel, MD, Guillermo Deben, MD, Miguel A. Sanz, MD

Blood (2004) 104 (11): 394.

https://doi.org/10.1182/blood.V104.11.394.394

Published: 2004

Journal Articles

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Martin S. Tallman, Janet W. Andersen, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, William G. Woods, Angela Ogden, Howard Weinstein, Lois Shepherd, Cheryl Willman, Clara D. Bloomfield, Jacob M. Rowe, Peter H. Wiernik

Blood (2002) 100 (13): 4298–4302.

https://doi.org/10.1182/blood-2002-02-0632

Published: 2002

Journal Articles

Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome: Presented in part at the meeting of the American Society of Hematology, San Diego, CA, December 1997.

Martin S. Tallman, Janet W. Andersen, Charles A. Schiffer, Frederick R. Appelbaum, James H. Feusner, Angela Ogden, Lois Shepherd, Jacob M. Rowe, Christopher François, Richard S. Larson, Peter H. Wiernik

Blood (2000) 95 (1): 90–95.

https://doi.org/10.1182/blood.V95.1.90

Published: 2000

NARROW

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

Analysis of the Serum Free Light Chain Ratio and Its Prognostic Value in a Cohort of Patients with Chronic Lymphocytic Leukemia.

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.

Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Maintenance Therapy with Thalidomide/Prednisone Post Autologous Stem-Cell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly Factor VIII Levels.

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.

All- trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Presented in part at the 39th meeting of the American Society of Hematology, New Orleans, LA, December 1999.

Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome: Presented in part at the meeting of the American Society of Hematology, San Diego, CA, December 1997.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only